



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

| | |
|---------------|----------------------------|
| Last Trade: | 17.23 |
| Trade Time: | 4:00 PM ET Feb 16, 2018 |
| Change: | 0.18 (+1.026%) |
| Day Range | 17.05 - 17.40 |
| 52-Week Range | 3.90 - 24.45 |
| Volume | 714,117 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 14, 2018

[Dynavax to Present at the RBC Capital Markets Global Healthcare Conference](#)

Feb 2, 2018

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Jan 12, 2018

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Jan 8, 2018

[Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults](#)

Jan 4, 2018

[Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

Feb 21, 2018 1:35 PM ET

[RBC Capital Markets Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)